Helus Pharma Appoints Jill Conwell as Chief People Officer to Support Clinical Advancement and Growth

Helus Pharma has appointed Jill Conwell as chief people officer, effective immediately. Conwell brings more than 20 years of leadership experience in the life sciences industry, with expertise in organizational strategy, talent development, corporate communications and investor relations. She has previously held senior leadership roles at Aclaris Therapeutics, Idera Pharmaceuticals and Shire Pharmaceuticals, where she helped build and scale organizations during periods of growth and pipeline advancement.

Helus Pharma said Conwell will help guide its talent strategy and organizational development as the company advances its clinical programs and prepares for its next phase of growth. The company is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists, which are synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland. For company updates and to learn more about Helus Pharma, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP. This appointment comes as the company advances its clinical-stage pharmaceutical programs developing novel serotonergic agonists to address mental health conditions, positioning the organization for its next growth phase through strategic talent leadership.